Insmed Statistics
Total Valuation
Insmed has a market cap or net worth of $12.34 billion. The enterprise value is $12.46 billion.
Important Dates
The last earnings date was Thursday, May 8, 2025, before market open.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Insmed has 182.14 million shares outstanding. The number of shares has increased by 20.00% in one year.
| Current Share Class | 182.14M |
| Shares Outstanding | 182.14M |
| Shares Change (YoY) | +20.00% |
| Shares Change (QoQ) | +1.03% |
| Owned by Insiders (%) | 0.87% |
| Owned by Institutions (%) | 100.20% |
| Float | 167.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 29.40 |
| Forward PS | 21.85 |
| PB Ratio | 119.38 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 32.71 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.86, with a Debt / Equity ratio of 13.17.
| Current Ratio | 5.86 |
| Quick Ratio | 5.21 |
| Debt / Equity | 13.17 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9.76 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -36.25% |
| Return on Invested Capital (ROIC) | -46.53% |
| Return on Capital Employed (ROCE) | -54.94% |
| Revenue Per Employee | $299,788 |
| Profits Per Employee | -$797,218 |
| Employee Count | 1,271 |
| Asset Turnover | 0.26 |
| Inventory Turnover | 0.98 |
Taxes
In the past 12 months, Insmed has paid $4.03 million in taxes.
| Income Tax | 4.03M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +160.88% in the last 52 weeks. The beta is 0.84, so Insmed's price volatility has been lower than the market average.
| Beta (5Y) | 0.84 |
| 52-Week Price Change | +160.88% |
| 50-Day Moving Average | 72.69 |
| 200-Day Moving Average | 73.53 |
| Relative Strength Index (RSI) | 43.65 |
| Average Volume (20 Days) | 2,671,115 |
Short Selling Information
The latest short interest is 15.78 million, so 8.66% of the outstanding shares have been sold short.
| Short Interest | 15.78M |
| Short Previous Month | 15.12M |
| Short % of Shares Out | 8.66% |
| Short % of Float | 9.42% |
| Short Ratio (days to cover) | 5.33 |
Income Statement
In the last 12 months, Insmed had revenue of $381.03 million and -$1.01 billion in losses. Loss per share was -$5.89.
| Revenue | 381.03M |
| Gross Profit | 291.47M |
| Operating Income | -859.01M |
| Pretax Income | -799.73M |
| Net Income | -1.01B |
| EBITDA | -849.84M |
| EBIT | -859.01M |
| Loss Per Share | -$5.89 |
Full Income StatementBalance Sheet
The company has $1.20 billion in cash and $1.31 billion in debt, giving a net cash position of -$106.43 million or -$0.58 per share.
| Cash & Cash Equivalents | 1.20B |
| Total Debt | 1.31B |
| Net Cash | -106.43M |
| Net Cash Per Share | -$0.58 |
| Equity (Book Value) | 99.16M |
| Book Value Per Share | 0.55 |
| Working Capital | 1.16B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$761.94 million and capital expenditures -$27.31 million, giving a free cash flow of -$789.25 million.
| Operating Cash Flow | -761.94M |
| Capital Expenditures | -27.31M |
| Free Cash Flow | -789.25M |
| FCF Per Share | -$4.33 |
Full Cash Flow StatementMargins
Gross margin is 76.49%, with operating and profit margins of -225.44% and -265.93%.
| Gross Margin | 76.49% |
| Operating Margin | -225.44% |
| Pretax Margin | -264.87% |
| Profit Margin | -265.93% |
| EBITDA Margin | -223.04% |
| EBIT Margin | -225.44% |
| FCF Margin | n/a |
Dividends & Yields
Insmed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.00% |
| Shareholder Yield | -20.00% |
| Earnings Yield | -8.20% |
| FCF Yield | -6.39% |
Dividend DetailsAnalyst Forecast
The average price target for Insmed is $95.29, which is 40.65% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $95.29 |
| Price Target Difference | 40.65% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (5Y) | 66.59% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on March 3, 2011. It was a reverse split with a ratio of 0.1:1.
| Last Split Date | Mar 3, 2011 |
| Split Type | Reverse |
| Split Ratio | 0.1:1 |
Scores
Insmed has an Altman Z-Score of -0.23 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.23 |
| Piotroski F-Score | 3 |